Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 75.04 USD -5.01% Market Closed
Market Cap: 1.1B USD

Inhibrx Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Inhibrx Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Inhibrx Inc
NASDAQ:INBX
Cash from Operating Activities
-$194.4m
CAGR 3-Years
-34%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Inhibrx Inc
Glance View

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.

INBX Intrinsic Value
0.97 USD
Overvaluation 99%
Intrinsic Value
Price

See Also

What is Inhibrx Inc's Cash from Operating Activities?
Cash from Operating Activities
-194.4m USD

Based on the financial report for Dec 31, 2024, Inhibrx Inc's Cash from Operating Activities amounts to -194.4m USD.

What is Inhibrx Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-43%

Over the last year, the Cash from Operating Activities growth was -1%. The average annual Cash from Operating Activities growth rates for Inhibrx Inc have been -34% over the past three years , -43% over the past five years .

Back to Top